Biotech/Biomedical
News Category
GeoVax Advances GEO-MVA Vaccine Program Toward Phase 3 Trial with Clinical Product Release
GeoVax completes release testing for GEO-MVA clinical supplies, enabling a pivotal Phase 3 immune bridging study under EMA guidance to address critica...
VolitionRx Reports Over 95% Early-Stage Cancer Detection Using Capture-Seq Technology
VolitionRx announced proof-of-concept data showing over 95% sensitivity for stage I and II cancers using its Capture-Seq liquid biopsy technology, tar...
Redwood AI Launches Chemical Risk Assessment Initiative, Appoints Stanford Chemist as Scientific Advisor
Redwood AI Corp. has initiated a Chemical Risk Assessment Module for its Reactosphere platform and appointed Stanford chemist Dr. Noah Burns as scient...
VERAXA Biotech Showcases BiTAC Cancer Platforms Ahead of BIO International Convention
VERAXA Biotech highlights partnering opportunities for its BiTAC-ADC and BiTAC-TCE platforms, backed by new proof-of-concept data, at the upcoming BIO...
Quantum BioPharma’s Lucid-MS Targets Myelin Repair in Multiple Sclerosis, Poised for Phase 2 Trials
Quantum BioPharma is advancing Lucid-MS, a first-in-class neuroprotective therapy for multiple sclerosis that directly targets myelin repair, toward P...
Onco-Innovations Limited Announces C$5 Million Private Placement to Advance ONC010 Program
Onco-Innovations has secured C$5 million in private placement funding to advance its ONC010 cancer treatment program and SynoGraph platform.
Onco-Innovations Achieves Key Manufacturing Milestone for ONC010 Drug Candidate
Onco-Innovations completed a successful 300-gram scale-up batch of its ONC010 API with 99.3% purity, advancing its PNKP inhibitor program toward clini...
VERAXA Biotech Showcases BiTAC Cancer Platforms Ahead of BIO International Convention
VERAXA Biotech AG is highlighting its BiTAC-ADC and BiTAC-TCE platforms, which show potential for improving cancer treatment precision and reducing of...
Knight Therapeutics Repays $60 Million Credit Facility Used for Paladin Acquisition
Knight Therapeutics has fully repaid its revolving credit facility drawn to finance the Paladin acquisition, using operational cash flow, while mainta...
Foreign Investors Add $206 Billion to U.S. Securities in April, Treasury Reports
Foreign investors purchased a net $206.0 billion of long-term U.S. securities in April, signaling continued demand for U.S. assets despite geopolitica...
I Bonds Offer 4.26% Composite Rate for May-October 2026 Issue
Series I Savings Bonds provide a 4.26% composite rate for bonds issued between May and October 2026, offering inflation protection backed by the U.S. ...
Quantum BioPharma’s Lucid-MS Targets Myelin Repair in Multiple Sclerosis, Advancing to Phase 2 Trials
Quantum BioPharma’s novel drug candidate Lucid-MS, which directly targets myelin repair, is preparing for phase 2 trials, offering a potential shift i...
Next-Generation DNA Repair Therapies Open New Frontiers in Oncology
The expansion of DNA Damage Response inhibitors beyond PARP inhibitors, led by companies like Onco-Innovations, AstraZeneca, and Boundless Bio, is dri...
Fed Holds Rates Steady, Hints at Potential Hike Later This Year Amid Inflation Concerns
The Federal Reserve kept benchmark lending rates unchanged but signaled possible rate hikes later in 2023 due to inflation risks from high energy pric...
Nightfood Holdings Highlighted for AI Infrastructure Automation Opportunity in Audio Editorial
Nightfood Holdings, through its TechForce Robotics division, was featured in an audio editorial discussing the growing demand for automation solutions...
Onco-Innovations Targets Next Wave of DNA Damage Response Cancer Therapies with PNKP Inhibitor
Onco-Innovations is advancing ONC010, a nanoparticle-encapsulated PNKP inhibitor, positioning itself as a potential leader in a novel class of cancer ...
NanoViricides Ships NV-387 Oral Gummies to DRC for Phase II MPox Trial
NanoViricides has shipped its broad-spectrum antiviral candidate NV-387 to the Democratic Republic of Congo for a Phase II clinical trial against MPox...
BioUtah Participates in National Symposium on Biotechnology's Role in National Security
BioUtah joined the Biotech Across America State Symposium in Washington, D.C. to discuss how state and local biotech ecosystems strengthen national se...
Soligenix Nears Key Clinical Milestones as Zacks Report Highlights HyBryte and Dusquetide Prospects
Soligenix is approaching critical clinical readouts in 2026, including the Phase 3 FLASH2 trial for HyBryte in CTCL and progress with dusquetide for B...
Landmark Proton Therapy Data Changes the Conversation; LIXTE Biotechnology (LIXT) Saw It Coming
A landmark Phase III trial shows proton therapy significantly improves survival for oropharyngeal cancer patients, validating LIXTE Biotechnology's st...
HeartBeam Partners With Mount Sinai to Advance AI-Powered ECG Technology
HeartBeam (BEAT) collaborates with Mount Sinai to develop and validate AI-based ECG algorithms, aiming to enhance personalized cardiac monitoring and ...
Okogen Acquires Ranpirnase Assets, Expanding Antiviral Pipeline Beyond Ophthalmology
Okogen Inc. has acquired the global intellectual property and development assets for ranpirnase from Orgenesis Inc., strengthening its ophthalmic prog...
NeuroOne Completes Limited Market Release of OneRF Trigeminal Nerve Ablation System, Reports 100% Pain Freedom in Initial 12 Patients
NeuroOne Medical Technologies announced that all 12 patients treated with its OneRF Trigeminal Nerve Ablation System during a limited market release r...
Lexaria Expands Patent Portfolio with Five New Grants, Including Two for GLP-1 Diabetes Treatments
Lexaria Bioscience Corp. received five new patents, including two for diabetes treatment using its DehydraTECH technology with GLP-1 drugs, strengthen...
Oragenics Reports Going Concern Audit Opinion, Raising Questions About Financial Stability
Oragenics Inc. disclosed a going concern audit opinion for fiscal 2025, highlighting potential financial risks as it advances its lead concussion trea...
Soligenix Receives EU Orphan Drug Designation for Dusquetide in Behçet Disease
Soligenix announced EU orphan drug designation for dusquetide in Behçet disease, providing up to 10 years of market exclusivity and advancing its inna...
NextPlat Partners With HealthWarehouse to Expand Nationwide Healthcare Fulfillment
NextPlat Corp. partners with HealthWarehouse.com to enable nationwide prescription and OTC fulfillment, expanding its U.S. healthcare footprint beyond...
Planet Ventures Invests in Space Robotics Startup General Astronautics at $40 Million Valuation
Planet Ventures Inc. has made a $100,000 strategic investment in General Astronautics, a Y Combinator-backed space robotics company developing autonom...
Soligenix Reports 2025 Results, Highlights Phase 3 CTCL Progress and Orphan Drug Milestones
Soligenix announced progress in its Phase 3 FLASH2 trial for cutaneous T-cell lymphoma and orphan drug designation for dusquetide in Behçet’s Disease,...
Nutriband Selects Global Brand Name for AVERSA Fentanyl Patch, Targeting Abuse Deterrence
Nutriband announced the selection of a proposed worldwide brand name for its abuse-deterrent fentanyl patch, aiming to be the first such product to re...
Lantern Pharma Advances AI-Driven Oncology Pipeline With Multiple 2026 Milestones
Lantern Pharma reports continued progress in its AI-driven oncology pipeline, including the LP-300 Phase 2 HARMONIC trial and planned FDA discussions,...
Telomir Pharmaceuticals Submits IND for Telomir-1 Targeting Triple-Negative Breast Cancer
Telomir Pharmaceuticals has submitted an Investigational New Drug application to the FDA for Telomir-1, a novel oral therapy for advanced triple-negat...
Annovis Bio Highlights Buntanetap Development in The Scientist Publication
Annovis Bio's lead drug candidate buntanetap, featured in The Scientist, shows promise in Phase 3 trials for Alzheimer's and Parkinson's diseases.
Tonix Pharmaceuticals Reports Positive Phase 1 Data for Lyme Disease Prophylaxis Candidate TNX-4800
Tonix Pharmaceuticals announced Phase 1 results for TNX-4800, a long-acting monoclonal antibody for Lyme disease prevention, showing sustained protect...
HeartBeam Inc. Achieves Key Regulatory Milestone, Analyst Upgrade Signals Commercial Transition
HeartBeam received FDA clearance for its 12-lead ECG synthesis software, leading to an analyst upgrade and highlighting a pivotal shift toward commerc...
GeoVax Announces Warrant Inducement Transaction to Raise Approximately $863,000
GeoVax Labs has entered into a warrant inducement agreement with institutional investors to raise gross proceeds of about $863,000 by reducing the exe...
Vycor Medical Reports 17% Revenue Growth in 2025, Driven by International Expansion of ViewSite Brain Access System
Vycor Medical announced a 17% increase in total revenue to $1.86 million for 2025, driven by 18% growth in its Vycor Medical division, highlighting su...
LIXTE Biotechnology Expands LB-100 Clinical Trials Targeting Ovarian and Colon Cancers
LIXTE Biotechnology announces expanded clinical trials for its lead compound LB-100, aiming to address treatment challenges in ovarian clear cell carc...
LIXTE Biotechnology’s LB-100: A Unique PP2A Inhibitor in Clinical Development
LIXTE Biotechnology Holdings holds the world’s only clinical-stage PP2A inhibitor, LB-100, which enhances cancer cell sensitivity to therapies and dis...
Soligenix Expands Rare Disease Pipeline with UK Designation for SGX945
Soligenix's investigational therapy SGX945 receives Promising Innovative Medicine designation in the UK, underscoring its potential and the company's ...
Cardio Diagnostics Holdings: Addressing Cardiovascular Disease with AI-Powered Precision Medicine
Cardio Diagnostics Holdings leverages AI and epigenetic biomarkers to provide personalized cardiovascular insights, aiming to reduce the leading cause...
BioStem Technologies to Present at the 25th Annual Needham Virtual Healthcare Conference
BioStem Technologies will present at the Needham Virtual Healthcare Conference, highlighting its regenerative medicine products and technologies to in...
Lonza Nominates Stephen Fry as Independent Board Member
Lonza nominates former Eli Lilly executive Stephen Fry to its board, bringing expertise in organizational transformation and performance culture to su...
Nephros Expands Water Safety Capabilities With ASSE 12080 Certified Water Management Planning Expertise
Nephros has earned an ASSE 12080 certification, enabling it to offer water management program consulting services to healthcare facilities, thereby ex...
LIXTE Biotechnology Holdings Files 2025 Form 10-K, Highlights Transformational Year
LIXTE Biotechnology Holdings (NASDAQ: LIXT) filed its 2025 Form 10-K, detailing a year of leadership changes, clinical progress, acquisition of Liora ...
Lexaria Launches New Human Clinical Study Evaluating DehydraTECH-Semaglutide Tablets and Capsules Against Wegovy®
Lexaria Bioscience has initiated a 5-week human pilot study comparing two oral DehydraTECH-semaglutide formulations to commercial Wegovy® tablets, aim...
Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc., Highlighting Durable ZUNVEYL Adoption in Long-Term Care
Alpha Cognition's ZUNVEYL shows strong and repeat adoption in long-term care, with FY25 revenue of $10.2M and a 62% quarterly increase in bottles disp...
Gold Hovers Around $4,500 Amid Dollar Strength and Rate Cut Delays; Long-Term Outlook Remains Bullish
Gold trades in a tight range near $4,500 as a strong dollar and delayed rate cuts weigh on prices, but long-term structural drivers like de-dollarizat...